Bavarian Nordic A/S maintained earnings guidance for the year 2022. For the year, the company expects revenues to be between DKK 2,800 million to DKK 3,000 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
157.4 DKK | +1.17% | +3.08% | -11.27% |
04-30 | Bavarian Nordic Books EUR65 Million Order for Smallpox Vaccine | MT |
04-29 | Bavarian Nordic A/S Receives EUR 65 Million Contract to Supply Smallpox Vaccines for EU Strategic Reserve | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.27% | 1.75B | |
+26.08% | 662B | |
+21.93% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 289B | |
+13.68% | 234B | |
+4.63% | 198B | |
-10.51% | 194B | |
+8.08% | 167B |
- Stock Market
- Equities
- BAVA Stock
- News Bavarian Nordic A/S
- Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022